Stocktoria
Definium Therapeutics, Inc. DFTX
Nasdaq · XNAS · stock · Medicinal Chemicals & Botanical Products · website · IPO 2015-05-04
Definium Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $117.7M | $65.3M | $52.1M | $36.2M | $34.8M |
| Operating income | -$166.3M | -$103.9M | -$93.9M | -$66.3M | -$93.9M |
| Interest expense | $5.5M | $2.3M | $920,000 | — | — |
| Income tax | $0 | — | — | — | -$1.2M |
| Net income | -$183.8M | -$108.7M | -$95.7M | -$56.8M | -$93.0M |
| EPS (diluted) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 |
| Operating cash flow | -$131.6M | -$79.1M | -$64.4M | -$50.1M | -$45.8M |
| Cash & equivalents | $257.8M | $273.7M | $99.7M | $142.1M | $133.5M |
| Total assets | $440.1M | $302.2M | $124.5M | $170.0M | $164.0M |
| Total liabilities | $107.8M | $60.7M | $46.4M | $19.1M | $12.3M |
| Shareholders' equity | $332.3M | $241.4M | $78.1M | $150.9M | $151.7M |
Source: SEC EDGAR filings · CIK 0001813814 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.